Format
Deal Terms Analysis
Valuation Disconnects Driving a Spike in Earnouts in M&A
Deal Terms Analysis
Lower Middle-Market Mergers & Acquisitions Deals Report
Deal Terms Analysis
Life Sciences
2023 SRS Acquiom Life Sciences M&A Study
Deal Terms Analysis
2023 M&A Deal Terms and Trends for Private Equity Buyers
Deal Terms Analysis
Technology M&A Deal Terms and Trends
Deal Terms Analysis
Escrow and Payments
Effect of Representations and Warranties Insurance on Deal Terms
Deal Terms Analysis
Private M&A Deal Terms: An SRS Acquiom Quick Guide for M&A Advisors
Deal Terms Analysis
Tools and Tactics for Getting Deals Across the Finish Line
Deal Terms Analysis
Tools for Practitioners
Deal Terms for M&A Escrows - Statistics and Key Findings
Deal Terms Analysis
2023 M&A Deal Terms Study
Deal Terms Analysis
M&A Trends: PPAs and Claims Activity
Deal Terms Analysis
Post-Closing M&A Claims and Purchase Price Adjustments: Where Do They Stand Heading Into 2023?
Deal Terms Analysis
2022 PE-Buyer Deal Terms
Deal Terms Analysis
Tools for Practitioners
How M&A Advisors Use Deal Data to Improve the Due Diligence Process
Deal Terms Analysis
2022 M&A Deal Terms Study Update with Key Findings
Deal Terms Analysis
Tools for Practitioners
2022 M&A Claims Insights Report
Deal Terms Analysis
2022 Technology M&A Deals Special Report
Deal Terms Analysis
Tools for Practitioners
2022 M&A Deal Terms Study
Deal Terms Analysis
Life Sciences
Tools for Practitioners
2021 Life Sciences M&A Study
Deal Terms Analysis
Tools for Practitioners
2021 M&A Deal Terms Study Key Findings
Deal Terms Analysis
Tools for Practitioners
2021 M&A Deal Terms Study
Deal Terms Analysis
2020 M&A Claims Insights Report
Deal Terms Analysis
Shareholder Representation
What to Make of the Great Hill Case – The M&A Bar is Not Yet in Agreement on How Best to Address Merger Agreement Privilege Issues
Deal Terms Analysis
2020 Review: COVID-19 Impact on M&A Transactions
Deal Terms Analysis
M&A Deal Terms & Trends Pre- & Post-COVID-19
Deal Terms Analysis
Shareholder Representation
M&A: Who Owns the Attorney-Client Privilege After Closing?
Deal Terms Analysis
Tools for Practitioners
Escrow and Payments
2020 Buy-Side Reps and Warranties Insurance Deal Terms Update
Deal Terms Analysis
A First Look at the Impacts of Coronavirus on M&A Transactions
Deal Terms Analysis
Tools for Practitioners
Buyer Power Ratio
Deal Terms Analysis
Life Sciences
Life Sciences: Milestone Trends by Product Stage
Deal Terms Analysis
Life Sciences
Life Sciences: Timeline of Milestone Payments
Deal Terms Analysis
Shareholder Representation
Addressing Target Company Privilege in Merger Agreements Five Years after Great Hill v. SIG
Deal Terms Analysis
Shareholder Representation
Beware of Exclusions When Defining Net Working Capital in M&A Transactions
Deal Terms Analysis
Life Sciences
Tools for Practitioners
2019 Life Sciences Study Quick Reference Guide
Deal Terms Analysis
Life Sciences
Tools for Practitioners
2019 Life Sciences M&A Study
Deal Terms Analysis
Escrow and Payments
Allocation and Assignment of Interest
Deal Terms Analysis
Shareholder Representation
Tools for Practitioners
M&A Privilege: What to Make of the Great Hill Case— Who Owns the Attorney-Client Privilege After Closing and How Can it Really be Addressed?
Deal Terms Analysis
2018 M&A Claims Insights Report
Deal Terms Analysis
Shareholder Representation
Understanding Changes in Shareholder Consent Requirements
Deal Terms Analysis
Tools for Practitioners
Impact of “Buyer Power Ratio” on M&A Deal Terms
Deal Terms Analysis
Shareholder Representation
Definition of Purchase Price
Deal Terms Analysis
Shareholder Representation
Do Carveouts to Caps Work the Way You Intend?
Deal Terms Analysis
Shareholder Representation
M&A Conflict Waivers
Deal Terms Analysis
Shareholder Representation
Clarifying When Attorneys’ Fees Constitute Damages